GlassScriptPhysician profile
Carola H Fleener
NPI 1063510329
$1,577.49
in general payments reported to CMS, 2019-2025
21 companies · $88.61 in 2025
The $88.61 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $129 · 2021: $368 · 2022: $152 · 2023: $232 · 2024: $369 · 2025: $88.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $246.75 | 2019-2021 | |
| Pfizer INC. | $170.58 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $162.47 | 2021-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $149.17 | 2020-2023 | Doc Band |
| Ironshore Pharmaceuticals INC. | $148.27 | 2019 | |
| Corium, LLC | $121.35 | 2022-2024 | Azstarys |
| Sobi, INC | $85.84 | 2019-2023 | |
| Sanofi Pasteur INC. | $77.80 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $62.99 | 2023-2024 | Flumist Quadrivalent, Evusheld |
| Phadia US INC. | $59.57 | 2022-2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $42.66 | 2024 | |
| Verrica Pharmaceuticals INC. | $41.89 | 2024-2025 | Ycanth |
| Shire North American Group INC | $35.26 | 2019 | |
| Genentech USA, INC. | $31.22 | 2020 | |
| Cipher Pharmaceuticals US LLC | $29.76 | 2025 | Spinosad, Natroba |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.00 | 2024 | Spinraza |
| Biomarin Pharmaceutical INC. | $23.34 | 2024 | Voxzogo 1.2mg |
| Amneal Pharmaceuticals LLC | $18.84 | 2020 | |
| Collegium Pharmaceutical, INC. | $16.62 | 2025 | Jornay Pm |
| Tris Pharma INC | $15.98 | 2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carola Fleener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.